Dr. Martens (LON:DOCS) Trading Down 11.6% – Time to Sell?

Dr. Martens plc (LON:DOCS) shares fell 11.6% during mid-day trading on Tuesday . The company traded as low as GBX 65 and last traded at GBX 66.90. 9,032,986 shares changed hands during trading, an increase of 342% from the average session volume of 2,043,681 shares. The stock had previously closed at GBX 75.65.

More Dr. Martens News

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg Bank reaffirmed a “buy” rating on DOCS, which supports investor confidence in the brand and long-term growth potential. Broker Rating
• Negative Sentiment: Dr. Martens projected flat revenue for 2026 while saying it will scale back discounts — a move that should help margins but signals limited top-line growth near term, which is weighing on the share price. Revenue Guidance Article

Wall Street Analyst Weigh In

DOCS has been the topic of a number of analyst reports. Berenberg Bank reiterated a “buy” rating on shares of Dr. Martens in a research report on Tuesday. Peel Hunt reaffirmed a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Dr. Martens presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 6,000.

Dr. Martens Trading Down 11.6%

The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The business’s fifty day moving average is GBX 76.53 and its 200 day moving average is GBX 83.47. The firm has a market capitalization of £646.63 million, a price-to-earnings ratio of 39.35, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last announced its earnings results on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. Equities analysts predict that Dr. Martens plc will post 2.5809394 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Robert Hanson bought 96,000 shares of the business’s stock in a transaction on Friday, December 5th. The shares were purchased at an average price of GBX 79 per share, for a total transaction of £75,840. In the last quarter, insiders purchased 97,130 shares of company stock valued at $7,673,816. Insiders own 2.79% of the company’s stock.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.